Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Cell Infect Microbiol. 2022 Jun 20;12:916012. doi: 10.3389/fcimb.2022.916012. eCollection 2022.
Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost. By far, there are still no virus-specific therapeutics clinically available to treat B19V infection. Therefore, exploiting the potential targets with a deep understanding of the life cycle of B19V, are pivotal to the development of B19V-tailored effective antiviral approaches. This review will introduce antiviral agents blocking viral invasion, inhibiting the enzymes or regulatory proteins involved in DNA synthesis, and so on. Moreover, nanotechnology-enabled approaches against B19V will also be outlined and discussed through a multidisciplinary perspective involving virology, nanotechnology, medicine, pharmaceutics, chemistry, materials science, and other fields. Lastly, the prospects of the antiviral agents and nanosystems in terms of fabrication, clinical translation and potential breakthroughs will be briefly discussed.
细小病毒 B19（B19V）是一种人类致病病毒，可引起广泛的临床表现。除了支持和对症治疗外，唯一获得美国食品和药物管理局批准的治疗 B19V 的抗病毒药物是静脉注射免疫球蛋白，但疗效有限，成本高昂。到目前为止，临床上仍然没有针对细小病毒 B19 感染的特异性治疗药物。因此，深入了解细小病毒 B19 的生命周期，寻找有潜力的靶点，对于开发针对细小病毒 B19 的有效抗病毒方法至关重要。本综述将介绍抗病毒药物，包括阻止病毒入侵、抑制参与 DNA 合成的酶或调节蛋白等。此外，还将从病毒学、纳米技术、医学、药剂学、化学、材料科学等多学科角度概述和讨论纳米技术增强型抗病毒方法。最后，简要讨论了抗病毒药物和纳米系统在制造、临床转化和潜在突破方面的前景。
